GSK India Saves Tykerb Main Patent But Loses Claims On Salt Patent To Fresenius Kabi
This article was originally published in PharmAsia News
Executive Summary
Amid a series of patent related setbacks faced by global drug firms, GSK has safeguarded Tykerb against Fresenius Kabi.